Reduced nintedanib dose shows comparable efficacy to higher dose in IPF

HONOLULU — Risk for mortality and hospitalization did not differ between patients with idiopathic pulmonary fibrosis taking 100 mg or 150 mg nintedanib twice daily, according to a real-world analysis presented at the CHEST Annual Meeting.
A twice-daily dose of 150 mg nintedanib (Ofev, Boehringer Ingelheim) is supported by the phase 3 randomized controlled INBUILD trial; however, researchers note that clinicians tend to lower it to 100 mg because of side effects.
“In practice, a fraction of patients use 100 mg [nintedanib] twice a day due to side effects at the higher dose,”

HONOLULU — Risk for mortality and hospitalization did not differ between patients with idiopathic pulmonary fibrosis taking 100 mg or 150 mg nintedanib twice daily, according to a real-world analysis presented at the CHEST Annual Meeting.
A twice-daily dose of 150 mg nintedanib (Ofev, Boehringer Ingelheim) is supported by the phase 3 randomized controlled INBUILD trial; however, researchers note that clinicians tend to lower it to 100 mg because of side effects.
“In practice, a fraction of patients use 100 mg [nintedanib] twice a day due to side effects at the higher dose,”